Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

Here are the 3 I love going back to and the 3 I'm glad I saw once. Lions pull off stunning win that NFL hasn't seen in 54 ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

Once-weekly taspoglutide was superior to twice-daily ... and hypersensitivity reactions. Clearly, GLP-1 receptor agonists may not be appropriate for all patients with type 2 diabetes, as they ...

Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) that require injection once a week or less are now available to prescribers in the form of Bydureon®(once-weekly exenatide).

Mazdutide – a once-weekly injectable Innovent licensed from ... said Innovent. Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) has been available in China for diabetes since 2021, and the ...

A 13-week extension of the previous phase 1/2 trial is also ongoing ... that is Metsera’s answer to the sector’s search for a ...

As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted ...

while newer GLP-1-targeting drugs like Ozempic and Wegovy, as well as Eli Lilly’s tirzepatide-based Mounjaro and Zepbound, only need to be given once a week, and orally-active formulations are ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...